30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Strategic Initiatives

BONESUPPORT Shifting to Direct Sales in US -

BONESUPPORT has terminated its present exclusive U.S. distribution agreement with Zimmer Biomet and will create its own U.S. commercial organization to support current and future U.S. product launches. BONESUPPORT's original distribution agreement with Biomet was signed in 2012; terms were extended in 1Q17. Direct sales will commence in October 2018. The present commercial organization will grow from 12 to 23 people. BONESUPPORT's bone void filler product will be joined by new CERAMENT formulations, as well as other bone graft substitute products. The company is pursuing a 2021 launch of CERAMENT-G antibiotic eluting product, and will also develop partnerships to help complete its suite of bone graft offerings. (BONESUPPORT, 5/17/18)